No, I meant the money the company had to pay to get the drug in the 1st place. The GBM drug was circa $10 million with milestone payments. The Cd17 drug was $750k with milestone payments. The NK drug was circa $75k with milestone payments.
Those numbers are from the top of my head, so check through the end of year reports and 4Cs for real numbers ( reckon I am close, though).
All of those payments, apart from future milestone payments, are completed. So almost $ 11 million of previous cash burn was just paying for the pipeline. Completion of this was a huge relief to future cash burn.
I think other posters have addressed the other bits in your post.
CHM Price at posting:
0.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)